XARELTO®: Venous thromboembolism (VTE) platform and
condition-specific dosing

XARELTO®: Venous thromboembolism (VTE) platform and condition-specific dosing

XARELTO® treats and helps protect against DVT/PE wherever your patients need itinpatient and outpatient*1-7

VTE Platform

Treatment and reduction in the risk of recurrence

VTE prophylaxis

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

*The decision regarding initiation setting should be based on the prescriber’s clinical judgment.

Administer 6 to 10 hours after surgery once hemostasis has been established.

Avoid use in patients with CrCl <15 mL/min.

§Discontinue XARELTO® in patients who develop acute renal failure while on treatment.

ǁCalculate CrCl based on actual weight.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO® is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 mL/min to <50 mL/min).

CrCl = creatinine clearance; DVT = deep vein thrombosis; HCP = healthcare professional; LTC = long-term care; PE = pulmonary embolism; VTE = venous thromboembolism.

Need Help?